80%Confidence
0Views
FDASource
2026-03-25Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance issues creates significant safety concerns for this popular diabetes/weight loss medication. This could temporarily disrupt supply and damage the reputation of this emerging pharmaceutical distributor in the competitive GLP-1 receptor agonist market.
Actionable: Investigate alternative Semaglutide suppliers and monitor for potential supply chain disruptions in the diabetes/weight loss medication sector.
AI Confidence: 80%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now